YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Neogen (NEOG) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items. This q…
Company Logo Biologics, biosimilars and personalized therapies are fueling CDMO outsourcing, while AI, automation and single-use systems enable scalable, compliant protein production. Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- "Recombinant…
Bio-Rad Laboratories (BIO) has drawn attention after recent share performance data showed a decline of about 2% over the past month, alongside a gain of roughly 27% over the past three months. At a share price of US$377.71, Bio-Rad Laborat…
Biodesix BDSX recently announced strategic progress in two molecular residual disease (MRD) programs to expand access to blood-based cancer monitoring. The company is developing tumor-informed and tumor-naive solutions that detect circulat…
Company Logo Demand is rising in diagnostics, precision medicine and biopharma research, while nanotechnology, automation and AI unlock targeted therapies and high-throughput workflows. Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Magnetic…
Company Logo Opportunities include automated closed systems, AI-enabled quality control, single-cell and cell therapy workflows, precision medicine, advanced diagnostics and emerging-market expansion. Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE…
Biodesix, Inc. Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise LOUISVILLE, Colo., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a lead…
Bio-Rad Laboratories, Inc. BIO is well poised to grow in the upcoming quarters, given the demand for its quality control and blood typing products in Clinical Diagnostics. In addition, growth across international markets boosts the stock's…
Company Logo Personalized medicine and chronic disease care are driving demand for TDM, with opportunities in consumables, automation, point-of-care devices, AI software and pharmacogenomics. Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "The…
Company Logo Demand is rising for real-time biomolecular analysis in drug discovery and diagnostics, driven by SPR/BLI advances, automation, high-throughput screening and biomarker research. Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Labe…
HERCULES, Calif., September 16, 2026--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K.…
Bio-Rad Laboratories has delivered a sharp mix of outcomes for long term holders, with the stock down about 52.9% over 5 years even as shorter term returns have turned positive. This puts the spotlight on what its current share price impli…
Company Logo The global transcriptome sequencing market is projected to reach $11.8 billion by 2035, growing at a 7.3% CAGR from 2025 to 2035. Growth is driven by falling sequencing costs, precision medicine, drug discovery, biomarker deve…
Photo by jarmoluk on Pixabay A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects. Illumina (ILMN), a maker of gene sequ…
A month has gone by since the last earnings report for Insulet (PODD). Shares have added about 8.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Insul…
Company Logo The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%;…
It has been about a month since the last earnings report for Bio-Rad Laboratories (BIO). Shares have added about 11.7% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend contin…
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
HERCULES, Calif., August 31, 2026--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lak…
Bio-Rad Laboratories BIO is balancing improving digital PCR demand and a recurring diagnostics base against a valuation that already discounts meaningful execution. Restructuring offers another path to better profitability, but near-term r…
Shares of Bio-Rad Laboratories BIO have climbed 19.1% in the past month, putting the durability of that momentum in focus. Digital PCR demand and steadier Clinical Diagnostics performance provide support. Yet Life Science demand remains we…
When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues to lead in financial scale, its bioproc…
According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $3…
Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 5 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Ruben ArguetaChief Executive Officer - Norman SchwartzPresident and Chief Operating Officer - Jonathan DiVincenzoExecutiv…
Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035" h…
Insight Molecular Diagnostics Inc. Discussions with FDA advance toward expected marketing authorization for GraftAssureDx FDA completes current portion of substantive review in a timely manner Favorable Medicare reimbursement policy issued…
Have you assessed how the international operations of Bio-Rad Laboratories (BIO) performed in the quarter ended June 2026? For this maker of instruments used in biomedical research, possessing an expansive global footprint, parsing the tre…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Q2 earnings and new guidance put Bio-Rad Laboratories in focus Bio-Rad Laboratories (BIO) drew in…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Biocon's updated valuation work now points to a fair value price target of ₹429.67, compared with the earlier figure of ₹416…
Bio-Rad Laboratories, Inc. Q2 2026 Earnings Call Summary - Moby Operational Drivers and Market Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #…
This article first appeared on GuruFocus. Total Revenue: Approximately $651 million in Q2 2026, essentially flat as reported and down 1.9% on a currency-neutral basis year-over-year. Life Science Revenue: $252 million, a decrease of 4.1% o…
Earnings Call Insights: Bio-Rad Laboratories (BIO) Q2 2026 MANAGEMENT VIEW * "Total company revenue in the second quarter was approximately $651 million, essentially flat as reported and down 1.9% on a currency-neutral basis compared with…
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.34 per share. This compares to earnings of $2.61 per share a year ago. These figures are adjusted for non-recurring…
HERCULES, Calif., August 04, 2026--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ende…
BOSTON, Aug. 4, 2026 /PRNewswire/ -- The 180 MW Phase II portion of the Millers Branch Solar Facility in Haskell County, Texas has achieved commercial operation. The capacity was contracted through Sustainability Roundtable, Inc's Net Zero…
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Precision Diagnostics And Medicine Market size & share revenue was valued at approxim…